Navigation Links
CIBC World Markets Equity Research Downgrades Target Price of BVF from $12.00 to a Staggering Low of $7.50 Based on Potential Incumbent Win in Proxy Battle

Not too late to Protect Your Investment and Vote for A Better Biovail

TORONTO, June 20 /PRNewswire/ - The Concerned Shareholders remind fellow shareholders of Biovail that it is not too late to vote your YELLOW proxy for a Better Biovail. It is more than clear that change is needed. Industry experts, CIBC World Markets - Equity Research, have today changed their recommendation for BVF to sector underperformer based on the proposed strategy of the Company going forward proposed by the Incumbent Board and management team.

According to CIBC, the reasons for this downgrade include:

(x) "Biovail's poor growth prospects, limited pipeline visibility and our

expectation for a long restructuring lead us to believe that Biovail

will underperform its peers going forward.

(x) In addition, we believe that Biovail's dividend policy is not

sustainable. We forecast declining cash flows and hold the view that

the company will need to use its cash to support distributions in the

near term. We would rather see the company preserve its capital for

eventual acquisitions.

(x) We also have modest expectations as it relates to Biovail's new focus

on Central Nervous System (CNS) disorders, as we view the clinical

development risks as relatively high and the existing market as

highly competitive. The CNS market is also highly genericized."

Furthermore, the report goes on to state that, "we believe the likelihood of a reduction or elimination of the dividend is quite high." CIBC wonders how "the company's current product portfolio will generate sufficient cash flows to support the payments given our impression that some of the company's products may be facing generic competition in the near term." Finally CIBC "fails to see how paying ~$240 million/year in dividends makes sense given the company's new strategy."

The Concerned Shareholders urge all shareholders to read the CIBC report in its entirety and agree with CIBC's analysis. The Concerned Shareholders fully align with CIBC's analysis that should the Incumbent Board and management win the proxy battle the price for BVF will dramatically fall. The status quo at Biovail is simply not acceptable. It is time to protect your investment and vote for change at Biovail.

It is not too late to cast your YELLOW proxy and support a forward thinking and innovative plan that relies on the leadership of independent, trusted and successful pharmaceutical sector entrepreneurs with a plan to evolve with the rate of change in the industry.

Even if you have already voted in favour of management, you may change your vote by completing and submitting a YELLOW proxy dated later than the previously submitted proxy.

For further information on how to vote your YELLOW proxy please visit and click on 'vote now'.

SOURCE A Better Biovail
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. World Vision Responding to Record Flooding in Midwest
2. Worldwide War Deaths Underestimated
3. Agendia Expands Laboratory Capacity at New Amsterdam Headquarters to Meet Increasing Demand for Services Worldwide
4. World research leaders gather in Finland to accelerate the development of bioactive paper
5. 10th World Congress on Gastrointestinal Cancer -- Barcelona, Spain
6. World Renowned Hand Surgeon Helps Patients Conquer Joint Discomfort Naturally
7. Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide
8. PartsSource Given 2008 World Class Customer Service Award for Second Straight Year
9. WORLDFOODS Provides All Natural Authentic Asian Sauces That Cater to Vegetarians, Celiacs and Those With Food Allergies
10. Essilor Agrees to Acquire Satisloh The World Leader in Optical Manufacturing Solutions
11. Rotary Brings the World to Los Angeles
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
Breaking Medicine Technology: